SCHEMBL678903

SCHEMBL678903

CS(=O)(=O)NC(=O)c1ccc(Oc2cccc(Cl)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 4/20 0.52
MCL1 Q07820 4/20 0.52
SCN9A Q15858 6/20 0.50
SCN2B O60939 1/20 0.49
SCN1A P35498 1/20 0.49
SCN1B Q07699 1/20 0.49
SCN5A Q14524 1/20 0.49
MMP1 P03956 2/20 0.47
MMP13 P45452 2/20 0.47
MMP2 P08253 1/20 0.47
MMP3 P08254 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP14 P50281 1/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16319859 0.86 MMP1 (0.56) BCL2L1MCL1SCN9ASCN2BSCN1B
SCHEMBL680466 0.85 EZH2 (0.54) BCL2L1MCL1SCN9ASCN2BSCN1A
SCHEMBL680286 0.85 PGR (0.60) BCL2L1MCL1SCN9ASCN2BSCN1A
SCHEMBL678831 0.84 BCL2L1 (0.52) BCL2L1MCL1SCN9ASCN2BSCN1A
SCHEMBL678844 0.84 SCN9A (0.53) SCN9ASCN2BSCN1ASCN1BSCN5A
SCHEMBL680556 0.83 SCN9A (0.68) BCL2L1MCL1SCN9ASCN5ASMN1; SMN2
SCHEMBL680348 0.83 SCN9A (0.53) SCN9ASCN2BSCN1ASCN1BSCN5A
SCHEMBL680674 0.83 SCN9A (0.57) BCL2L1MCL1SCN9ASCN5A
SCHEMBL679907 0.83 SCN9A (0.50) BCL2L1MCL1SCN9ASCN2BSCN1B
SCHEMBL679785 0.83 MCL1 (0.62) BCL2L1MCL1SCN9AMMP1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593427-B1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2014-12-24 EP disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010207-A1 Chemical Compounds SCN1A, SCN1B, SCN7A BCL2L1 3284/4885MCL1 2739/4885SCN9A 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.